Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101)

Background Adjuvant oral uracil-tegafur (UFT) has led to significantly longer postoperative survival among patients with non-small-cell lung cancer (NSCLC). Gemcitabine (GEM) monotherapy is also reportedly effective for NSCLC and has minor adverse events (AEs). This study compared the efficacy of GE...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of clinical oncology Vol. 26; no. 12; pp. 2216 - 2223
Main Authors:	Yamaguchi, Masafumi, Tada, Hirohito, Mitsudomi, Tetsuya, Seto, Takashi, Yokoi, Kohei, Katakami, Nobuyuki, Nakagawa, Kazuhiko, Oda, Makoto, Ohta, Mitsunori, Sawa, Toshiyuki, Yamashita, Motohiro, Iked, Norihiko, Saka, Hideo, Higashiyama, Masahiko, Nomori, Hiroaki, Semba, Hiroshi, Negoro, Shunichi, Chiba, Yasutaka, Shimokawa, Mototsugu, Fukuoka, Masahiro, Nakanishi, Yoichi
Format:	Journal Article
Language:	English
Published:	Singapore Springer Singapore 01-12-2021 Springer Nature B.V
Subjects:	Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy, Adjuvant Deoxycytidine - analogs & derivatives Gemcitabine Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - surgery Medicine Medicine & Public Health Non-small cell lung carcinoma Oncology Original Article Small cell lung carcinoma Surgical Oncology Tegafur Toxicity Uracil Uracil - therapeutic use Adjuvant chemotherapy Uracil-tegafur Gemcitabine NSCLC
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!